Free Trial
OTCMKTS:NURPF

Neuren Pharmaceuticals (NURPF) Stock Price, News & Analysis

Neuren Pharmaceuticals logo
C$8.00 +1.00 (+14.29%)
As of 05/2/2025 11:16 AM Eastern

About Neuren Pharmaceuticals Stock (OTCMKTS:NURPF)

Key Stats

Today's Range
C$8.00
C$8.00
50-Day Range
C$6.60
C$8.65
52-Week Range
C$6.60
C$14.25
Volume
100 shs
Average Volume
1,127 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Neuren Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
0th Percentile Overall Score

NURPF MarketRank™: 

Neuren Pharmaceuticals scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Neuren Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neuren Pharmaceuticals is -894.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neuren Pharmaceuticals is -894.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Neuren Pharmaceuticals has a short interest ratio ("days to cover") of 9365, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Neuren Pharmaceuticals has recently increased by 21.59%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Neuren Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Neuren Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Neuren Pharmaceuticals has a short interest ratio ("days to cover") of 9365, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Neuren Pharmaceuticals has recently increased by 21.59%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Neuren Pharmaceuticals has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Neuren Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for NURPF on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive NURPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NURPF Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Headlines

NURPF Stock Analysis - Frequently Asked Questions

Neuren Pharmaceuticals' stock was trading at C$7.57 on January 1st, 2025. Since then, NURPF shares have increased by 5.7% and is now trading at C$8.00.
View the best growth stocks for 2025 here
.

Shares of NURPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:NURPF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (OTCMKTS:NURPF) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners